CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC

Video

A brief overview of study design, patient demographics, data from the phase 1 CHRYSALIS trial, which assessed the safety and efficacy of amivantamab in patients with EGFR exon 20-mutated, advanced or metastatic NSCLC.

Related Videos
Experts on breast cancer
Expert on GVHD
Expert on breast cancer
Experts on breast cancer
Expert on GVHD
Experts on GVHD
Expert on breast cancer
Experts on breast cancer
Expert on GVHD
Expert on GVHD
Related Content